Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates - Scorecard - MDSpire

Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates

  • By

  • Ekaterina I. Ryabova

  • Artem A. Derkaev

  • Ilias B. Esmagambetov

  • Mikhail A. Dovgiy

  • Ilya V. Gordeychuk

  • Inna V. Shuliakova

  • Rosa M. Hossain

  • Anton A. Blinov

  • Anna A. Iliukhina

  • Daria M. Grousova

  • Ilya D. Zorkov

  • Daria V. Avdoshina

  • Stanislav A. Gulyaev

  • Vasiliy D. Apolokhov

  • Tatiana V. Gulyaeva

  • Irina A. Favorskaya

  • Dmitry V. Shcheblyakov

  • Alexander L. Gintsburg

  • Denis Y. Logunov

  • June 4, 2026

  • 0 min

Share

Clinical Scorecard: Sustained Efficacy of AAV Vector-Based SARS-CoV-2 Prevention in Murine Models and Non-Human Primates

At a Glance

CategoryDetail
Condition
Key MechanismsRecombinant adeno-associated virus (rAAV) delivery of neutralizing antibodies (source needed).
Target Population
Care Setting

Key Highlights

  • Single intramuscular administration of rAAV-P2C5-Fc provides long-term protective efficacy against SARS-CoV-2 variants (source needed).
  • Antibody levels remained protective for over 480 days in mice and up to 1,120 days in marmosets (source needed).
  • Biodistribution analysis showed minimal off-target spread of rAAV (source needed).
  • Moderate anti-AAV capsid antibody responses were detected; anti-drug antibodies against P2C5-Fc remained undetectable (source needed).

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Mice and common marmosets in preclinical studies

          Rapid onset and sustained expression of neutralizing antibodies following a single administration.

          Clinical Best Practices

            Related Resources & Content

              Original Source(s)

              Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates

              • by Ekaterina I. Ryabova, Artem A. Derkaev, Ilias B. Esmagambetov, Mikhail A. Dovgiy, Ilya V. Gordeychuk, Inna V. Shuliakova, Rosa M. Hossain, Anton A. Blinov, Anna A. Iliukhina, Daria M. Grousova, Ilya D. Zorkov, Daria V. Avdoshina, Stanislav A. Gulyaev, Vasiliy D. Apolokhov, Tatiana V. Gulyaeva, Irina A. Favorskaya, Dmitry V. Shcheblyakov, Alexander L. Gintsburg, Denis Y. Logunov

              • June 4, 2026

              Related Content

              The CRISPR-powered Diagnostic SLEUTH

              Novel DNA-guided system may support future RNA diagnostics and mutation detection

              • May 22, 2026

              • 2 min
              Permanent hypoparathyroidism following SARS-CoV-2 infection: a case report with two-year follow-up and literature review

              Dynamic hyperinflammatory response assessment using HIC scores in COVID-19: application to a large series of patients receiving anakinra